Compounding pharmacy market projected to hit 31B by 2034, personalised medicine push
Posted by elle_z in Research & News - 0 points, 7 comments.
BioSpace ran a piece projecting the US compounding pharmacy market will hit USD 31.77 billion by 2034, with personalised medicine demand cited as the main accelerant. It mentions things like multi-state licensing expansions and the broader shift toward individualised dosing and formulations.
My take is the growth number itself is not surprising. Once GLP-1s exploded off-label, and more people started asking about compounded peptides, BHRT, and custom hormone work, the whole industry basically had to scale up to keep up. What I am more curious about is the regulatory side. The FDA has been cracking down on mass compounding for things like semaglutide, so how do you square a 31B projection with a tightening legal environment?
Anyone here actually working in or following compounding pharmacy news closely? Wondering if the big growth is coming from legit personalised prescriptions, or if it is still mostly the grey-area stuff driving the numbers 😅
Comments
- honestgreg: Honestly the projection tracks with what I am seeing on my end, to be fair I only deal with it as a patient/customer so take it with a grain of salt. The BHRT side and custom thyroid stuff seems to be carrying a lot of that growth, not just GLP-1s. My guess is most of the actual dollars are legit 503A and 503B work, sterile hormone preparations and provider-written scripts for things that big pharma has no interest in making anymore. The grey area definitely inflated the numbers during the sema
- elle_z: Yeah the BHRT angle makes sense, i hadn't thought about that one carrying so much weight tbh. Big pharma really has stepped back from a lot of custom hormone stuff, so 503A/B outfits are filling that gap whether the FDA likes it or not 😅 The bit about grey area revenue not sticking is what gets me too. Like how much of that 31B is real sustained demand vs the compounding frenzy that came with the semaglutide shortage and will dry up. You reckon the legit personalised side is enough to carry th
- fasted_scientist: (503A and 503B distinction is the bit most casual users don't even know exists, ngl) fair point on the legit work carrying most of it long term. But "how much sticks" is the real question, isn't it. If a chunk of those scripts were basically shortage workarounds and the FDA tightens up, that revenue doesn't just vanish, it shifts to the big brands. Curious what that does to the smaller compounders who built around peptide demand specifically. They can't exactly pivot to mass producing ozempic p
- elle_z: Yeah exactly that shift is what worries me too honestly. The small shops that leaned hard into semaglutide and tirz short supplies are kind of exposed now if the FDA keeps squeezing. They don't have the capital to pivot to 503B sterile lines or branded licensing deals. Some will probably consolidate into bigger networks, others just close shop. The legit hormone and BHRT work keeps the lights on but it's a slower margin business than peptides were during the boom.
- humbleomar229: Honestly probably not on its own, at least not yet. The personalised stuff is growing but it's still a fraction compared to what GLP-1 demand did for those 503A shops the last couple years. Once the shortage fully resolves a lot of that revenue just... Evaporates.
- weekendnate: Yeah, the shortage boom was a one-time tailwind and you're right that it won't repeat. The question is whether the compounding side can transition into actual personalised medicine work, or if it just shrinks back to its old niche once the cash cow dries up.
- elle_z: Yeah that tracks. I was thinking the same thing about the shortage resolution cliff, like once the innovator products are back in stock those 503A scripts basically dry up overnight. So does the 31B projection bake in that drop or is it assuming the personalised side fills the gap fast enough to compensate?
Community discussion - research and educational context only. Not medical advice.